Explore the vast range of titles available.

Up to 7% of term and late-preterm neonates in high-income countries receive antibiotics during the first 3 days of life because of suspected early-onset sepsis. The prevalence of culture-proven early-onset sepsis is 0·1% or less in high-income countries, suggesting substantial overtreatment. We assess whether procalcitonin-guided decision making for suspected early-onset sepsis can safely reduce the duration of antibiotic treatment. We did this randomised controlled intervention trial in Dutch (n=11), Swiss (n=4), Canadian (n=2), and Czech (n=1) hospitals. Neonates of gestational age 34 weeks or older, with suspected early-onset sepsis requiring antibiotic treatment were stratified into four risk categories by their treating physicians and randomly assigned [1:1] using a computer-generated list stratified per centre to procalcitonin-guided decision making or standard care-based antibiotic treatment. Neonates who underwent surgery within the first week of life or had major congenital malformations that would have required hospital admission were excluded. Only principal investigators were masked for group assignment. Co-primary outcomes were non-inferiority for re-infection or death in the first month of life (margin 2·0%) and superiority for duration of antibiotic therapy. Intention-to-treat and per-protocol analyses were done. This trial was registered with ClinicalTrials.gov, number NCT00854932. Between May 21, 2009, and Feb 14, 2015, we screened 2440 neonates with suspected early-onset sepsis. 622 infants were excluded due to lack of parental consent, 93 were ineligible for reasons unknown (68), congenital malformation (22), or surgery in the first week of life (3). 14 neonates were excluded as 100% data monitoring or retrieval was not feasible, and one neonate was excluded because their procalcitonin measurements could not be taken. 1710 neonates were enrolled and randomly assigned to either procalcitonin-guided therapy (n=866) or standard therapy (n=844). 1408 neonates underwent per-protocol analysis (745 in the procalcitonin group and 663 standard group). For the procalcitonin group, the duration of antibiotic therapy was reduced (intention to treat: 55·1 vs 65·0 h, p<0·0001; per protocol: 51·8 vs 64·0 h; p<0·0001). No sepsis-related deaths occurred, and 9 (<1%) of 1710 neonates had possible re-infection. The risk difference for non-inferiority was 0·1% (95% CI −4·6 to 4·8) in the intention-to-treat analysis (5 [0·6%] of 866 neonates in the procalcitonin group vs 4 [0·5%] of 844 neonates in the standard group) and 0·1% (−5·2 to 5·3) in the per-protocol analysis (5 [0·7%] of 745 neonates in the procalcitonin group vs 4 [0·6%] of 663 neonates in the standard group). Procalcitonin-guided decision making was superior to standard care in reducing antibiotic therapy in neonates with suspected early-onset sepsis. Non-inferiority for re-infection or death could not be shown due to the low occurrence of re-infections and absence of study-related death. The Thrasher Foundation, the NutsOhra Foundation, the Sophia Foundation for Scientific research.

Finding out you are pregnant, particularly as a teen, can be a frightening and disorienting experience. This text guides readers through important first steps to taking on a potential journey to parenthood, from telling your parents, to finding a medical practitioner, or deciding to terminate a pregnancy. Readers are encouraged to build a support network and to forge a path forward that is comfortable for them, whatever it may be. This text includes a glossary, a \"For More Information\" section, and suggestions for additional research to guide students in their reading.

In preterm infants with patent ductus arteriosus, expectant management was noninferior to ibuprofen therapy with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks.

Choosing to become a mother is a difficult choice for any woman. It can be especially difficult for teen mothers without the right kind of support and information. Support is provided within the text, as is the necessary information a new teen mom needs to prepare for the birth of her baby and the first few years of her baby's life.

Respiratory failure is a leading cause of neonatal mortality in the developing world. Bubble continuous positive airway pressure (bCPAP) is a safe, effective intervention for infants with respiratory distress and is widely used in developed countries. Because of its high cost, bCPAP is not widely utilized in low-resource settings. We evaluated the performance of a new bCPAP system to treat severe respiratory distress in a low resource setting, comparing it to nasal oxygen therapy, the current standard of care. We conducted a non-randomized convenience sample study to test the efficacy of a low-cost bCPAP system treating newborns with severe respiratory distress in the neonatal ward of Queen Elizabeth Central Hospital, in Blantyre, Malawi. Neonates weighing >1,000 g and presenting with severe respiratory distress who fulfilled inclusion criteria received nasal bCPAP if a device was available; if not, they received standard care. Clinical assessments were made during treatment and outcomes compared for the two groups. 87 neonates (62 bCPAP, 25 controls) were recruited. Survival rate for neonates receiving bCPAP was 71.0% (44/62) compared with 44.0% (11/25) for controls. 65.5% (19/29) of very low birth weight neonates receiving bCPAP survived to discharge compared to 15.4% (1/13) of controls. 64.6% (31/48) of neonates with respiratory distress syndrome (RDS) receiving bCPAP survived to discharge, compared to 23.5% (4/17) of controls. 61.5% (16/26) of neonates with sepsis receiving bCPAP survived to discharge, while none of the seven neonates with sepsis in the control group survived. Use of a low-cost bCPAP system to treat neonatal respiratory distress resulted in 27% absolute improvement in survival. The beneficial effect was greater for neonates with very low birth weight, RDS, or sepsis. Implementing appropriate bCPAP devices could reduce neonatal mortality in developing countries.

Provides a guide to the first twelve months of life with a new baby, including information on feeding, immunizations, development, sleeping, and medical care.

This multicenter trial comparing nasal high-flow therapy with CPAP as primary support for preterm infants with respiratory distress showed a significantly higher treatment-failure rate with high-flow therapy. In 2014, there were more than 380,000 preterm births (i.e., births at a gestational age of <37 weeks) in the United States, accounting for approximately 10% of all births that year. 1 Preterm infants have a risk of the respiratory distress syndrome. The introduction of endotracheal ventilation has improved the survival rate among preterm infants but is associated with an increased risk of complications such as bronchopulmonary dysplasia. 2 Clinicians aim to use noninvasive respiratory support to minimize the risk of such complications. The most widely used noninvasive approach, nasal continuous positive airway pressure (CPAP), has been shown to be an effective . . .

Using a unique chronological structure that helps parents navigate baby's first 365 days, \"Baby Day by Day\" provides new parents with everything they need to know about looking after their child, from birth to twelve months. Written by a panel of pediatricians, child psychologists, nutritionists, and complementary medicine experts, \"Baby Day by Day\" provides an unbiased approach to baby care that gives the pros and cons of various approaches, including sleep training, managing crying, and breastfeeding issues. Providing answers to common queries and baby dilemmas, suggestions for age-appropriate games and developmentally stimulating things to do with your baby, as well as a comprehensive health section discussing common childhood ailments, \"Baby Day by Day\" also looks at the most recent discoveries about how babies' minds work and how parents can use these insights to guide their child's development.

This multicenter, randomized trial of hypoglycemia treatment in otherwise healthy newborns at risk for hypoglycemia compared cognitive and motor outcome scores at 18 months for a traditional treatment threshold (glucose concentration of <47 mg per deciliter) and a lower threshold (glucose concentration of <36 mg per deciliter). The lower threshold was noninferior to the traditional threshold.